Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PHOX2B PC-CAR T Cells for Relapsed Neuroblastoma
NCT07007117Phase 1Active, not recruiting
- Start
- Jun 2025
- Primary completion
- Jun 2032
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of PHOX2B PC-CAR T in neuroblastoma (2 arms). Primary endpoints: Maximum Tolerated Dose at 5 years and Adverse Events at 5 years. Started Jun 2025; status: active, not recruiting.
02
Drugs
PHOX2B PC-CAR T
03
Conditions
neuroblastoma
Beyond the preview
Go deeper on NCT07007117.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07007117.